EMA: European Vaccine Approval

The European Medicines Agency (EMA) is responsible for the scientific evaluation of medicines in the European Union. Through its centralized procedure, EMA assesses vaccine quality, safety, and efficacy, enabling marketing authorization valid across all 27 EU member states plus Iceland, Liechtenstein, and Norway.

Centralized Procedure

The centralized procedure is mandatory for certain medicines, including vaccines:

• Single application covers all EU/EEA member states
• One marketing authorization valid in all 30 countries
• Mandatory for biologics, including vaccines
• Provides access to the entire EU market simultaneously

CHMP Review Process

The Committee for Medicinal Products for Human Use (CHMP) conducts the scientific review:

1. Manufacturer submits Marketing Authorization Application (MAA)
2. CHMP assigns two "rapporteur" countries to lead review
3. Comprehensive assessment of quality, safety, efficacy
4. Peer review by other committee members
5. Opinion issued (positive or negative)
6. European Commission grants final authorization

European Public Assessment Reports (EPARs)

EMA vs. FDA: Key Differences

• Geographic scope: EMA covers 30 countries; FDA covers US only
• Process: EMA uses rapporteur system; FDA uses internal review
• Transparency: EMA publishes more detailed assessment data
• Timeline: Similar review times (10-12 months standard)
• Advisory committees: Both convene expert committees

Sources & Citations

• EMA: Centralized Procedure
• EMA: Home